BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Veopoz (Pozelimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Veopoz (Pozelimab)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06479863-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Veopoz (Pozelimab): Phase 1 readout est. (NCT06479863)
DESCRIPTION:Veopoz (Pozelimab)\, phase 1.\nStudy: Efficacy and Safety of Po
 zelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclu
 sion Body Myositis\nEstimated primary completion: 30 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pozelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06479863
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230834-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Veopoz (Pozelimab): Phase 1 readout est. (NCT07230834)
DESCRIPTION:Veopoz (Pozelimab)\, phase 1\, Age-Related Macular Degeneration
 .\nStudy: Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adul
 t Participants\nEstimated primary completion: 3 July 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pozelimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07230834
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT06541704)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Age-Related Macular Degeneration
 .\nStudy: A Study Investigating Subcutaneously Administered Pozelimab in C
 ombination With Cemdisiran or Cemdisiran Alone in Adult Participants With 
 Geographic Atrophy\nEstimated primary completion: 31 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pozelimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744921-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT05744921)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobi
 nuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemd
 isiran Combination Therapy is and How Well it Works\nEstimated primary com
 pletion: 10 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05744921
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154745-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20300118
DTEND;VALUE=DATE:20300119
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT07154745)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study to Evaluate How Pozelimab + Cemdisiran Combination Th
 erapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PN
 H) Whose Current Treatment is Not Working Efficiently\nEstimated primary c
 ompletion: 18 January 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07154745
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142343-5167@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20300212
DTEND;VALUE=DATE:20300213
SUMMARY:Veopoz (Pozelimab): Phase 4 readout est. (NCT07142343)
DESCRIPTION:Veopoz (Pozelimab)\, phase 4.\nStudy: A Study to Test the Safet
 y of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare D
 isease Called CHAPLE (Complement Hyperactivation\, Angiopathic Thrombosis\
 , Protein-losing Enteropathy) Disease\nEstimated primary completion: 12 Fe
 bruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pozelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 142343
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
